News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Health Canada Approves Swedish Orphan Biovitrum's Alprolix™


3/21/2014 8:32:51 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Swedish Orphan Biovitrum AB's (pupl) (Sobi) partner Biogen Idec today announced that Health Canada has approved Alprolix(TM) (Coagulation Factor IX (Recombinant), Fc fusion protein), rFIXFc, for the control and prevention of bleeding episodes and routine prophylaxis in adults, and children aged 12 and older, with haemophilia B. Alprolix is the first approved long-acting haemophilia B therapy and is indicated to prevent or reduce the frequency of bleeding episodes with prophylactic injections scheduled once weekly or once every 10-14 days.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES